← 產業報告目錄
Lipid Nanoparticles (LNPs) CDMO Market Size, Share & Trends Analysis Report By Product (mRNA , Plasmid DNA (pDNA), siRNA, saRNA, microRNA, and Others), Scale Of Operation (Preclinical, Clinical , and Commercial), End-Users, By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-09頁數 190報告編號 INSIGHTACE-4310be2215
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2024 valuation of USD 205.4 Mn, the global Lipid Nanoparticles (LNPs) CDMO Market is poised to develop to USD 803.6 Mn by 2034, demonstrating a CAGR of 14.8% during the 2025–2034 forecast window.
The Lipid Nanoparticles (LNPs) CDMO sector involves key industry insights & findings from the report:
The advent of lnps represents aroused due to a high prevalence of infectious diseases, rising healthcare expenditures, and medical applications of nanopartic. This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold substantial shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs) Snapshot
Chapter 4. Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs) Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis: Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
4.10. Application of mRNA Beyond COVID 19 Vaccine
Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. mRNA
5.2.2. Plasmid DNA (pDNA)
5.2.3. siRNA
5.2.4. saRNA
5.2.5. microRNA
5.2.6. Other Products
Chapter 6. Market Segmentation 2: By End-Users Estimates & Trend Analysis
6.1. By End-Users & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Users:
6.2.1. Pharmaceutical Companies
6.2.2. Academic Research Institute
6.2.3. Diagnostic Laboratory
Chapter 7. Market Segmentation 3: By Scale of Operation Estimates & Trend Analysis
7.1. By Scale of Operation & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operation:
7.2.1. Preclinical
7.2.2. Clinical
7.2.3. Commercial
Chapter 8. Lipid Nanoparticles (LNPs) CDMO Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By End-Users, 2021-2034
8.1.3. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
8.1.4. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, 2021-2034
8.2.3. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, 2021-2034
8.2.4. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, 2021-2034
8.3.3. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, 2021-2034
8.3.4. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, (US$ Million) 2021-2034
8.4.3. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
8.4.4. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
8.5.4. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Corden Pharma GmbH
9.2.2. eTheRNA
9.2.3. Curapath (Polypeptide Therapeutic Solutions (PTS))
9.2.4. FUJIFILM Corporation
9.2.5. ST Pharm Co Ltd
9.2.6. Exelead (Merck KGaA)
9.2.7. Avanti Polar Lipids, Inc. (Croda International Plc.)
9.2.8. Emergent CDMO
9.2.9. Esco Aster Pte Ltd
9.2.10.Vernal Biosciences
9.2.11.Recipharm AB
9.2.12.Ardena Holding NV
9.2.13.Curia Global, Inc.
9.2.14.Helix Biotech
9.2.15.Phosphorex Inc
9.2.16.Polymun Scientific Immunbiologische Forschung GmbH
9.2.17.Lonza Group AG
9.2.18.Evonik
9.2.19.Samsung Biologics
9.2.20.Catalent, Inc
9.2.21.Genevant Sciences
9.2.22. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們